NCT01718847View on ClinicalTrials.gov

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Increased Drug Resistance
Interventions
DRUG

NOV120101 (Poziotinib)

16 mg PO once daily until disease progression or unacceptable toxicity development

Trial Locations (5)

410-769

National Cancer Center, Goyang-si

361-711

Chungbuk National University Hospital, Cheongju-si

138-736

Asan Medical Center, Songpa-gu

682-714

Ulsan University Hospital, Dong-gu

405-760

Gachon University Gil Medical Center, Incheon

Sponsors
All Listed Sponsors
collaborator

Hanmi Pharmaceutical Company Limited

INDUSTRY

lead

National OncoVenture

OTHER

NCT01718847 - NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors | Biotech Hunter | Biotech Hunter